|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Item 5.07. |
Submission of Matters to a Vote of Security Holders.
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
|||
1,440,138
|
74,742
|
1,049
|
0
|
For
|
Against
|
Abstentions
|
Broker Non-Votes
|
|||
1,449,712
|
65,191
|
1,026
|
0
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
104
|
Cover Page Interactive Data File.
|
Cyclerion Therapeutics, Inc.
|
|||
Dated: July 19, 2023
|
By:
|
/s/ Anjeza Gjino
|
|
Name:
|
Anjeza Gjino
|
||
Title:
|
Chief Financial Officer
|
Document and Entity Information |
Jul. 19, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 19, 2023 |
Entity File Number | 001-38787 |
Entity Registrant Name | CYCLERION THERAPEUTICS, INC. |
Entity Central Index Key | 0001755237 |
Entity Incorporation, State or Country Code | MA |
Entity Tax Identification Number | 83-1895370 |
Entity Address, Address Line One | 245 First Street, 18th Floor |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02142 |
City Area Code | 857 |
Local Phone Number | 327-8778 |
Title of 12(b) Security | Common Stock, no par value |
Trading Symbol | CYCN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
RHY_U=3_ 102P,$% @ ;(OS5I>*NQS M $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M: (7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'FR-9V87YTC'?8Q' M]>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X 3[+O,&@EXN1 M:T/9=1,92L88!.R '<(Y_ A^[<#K3P&]'@!6^A C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R! M+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E< M)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-: M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% M @ ;(OS5B0>FZ*M ^ $ !H !X;"]? M+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2 M*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+B MRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L# M!!0 ( &R+\U9ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM M;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL M>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE M@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J M1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/; M&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G= M560C2&2FKW@ALO7L^T%.6X.^D &PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( &R+\U;= EL7 &PO &PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !LB_-699!Y MDAD! #/ P $P @ ',$@ 6T-O;G1E;G1?5'EP97-=+GAM 7;%!+!08 "0 ) #X" 6% ! end
'-DM5=;;],P
M%'Y'XC^8O#N7=@5:K9M V]"DP= B3?D.J>MA>L$VUW;?X_MQ&EZ7=/ F^-S
MOHOM %LS" -D%F!4(.EJG@6BT6XZ(:9G!B2.(E^?G[XYI1]KA$2+ZH6J9R)WQO$
MRY'DGKH;V?"(**A<[.271I)^OQ^Y:)5JB-@1:B:4)H)"/3_5%:">W(N*H$]-
M@6WF*:#A)'N.3,"ML$K4$NM5#FJ_#Q..;-AB.CCNXF[BD:8T-H%CHD8.Y",;
M0DKJ0_E5J "84D'(%@L1(M-$FX-Q4^5DGC,QSLH9,V=W=.!/X0G&R.WQP!(.
M \5F.;<;Z.:F$L;#P)X]]J?\*Y<0&H<^168'.. +_*
MM?,&N$R2#::UV\ HAYL!D+MK"
2"57X8Y[0"E0&%*]F1";>Z6,I>K0%9%S?WNY9"T1/A3?
M2EKPK-!*K!JUC<$U.+NEV#Z('6E;KN";:9 LZA'M574FKRP'U >&-+DIK-Y=
M=